Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: AzaSite Eye Drops Clear all
Completed Phase 4 Interventional

Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis

NCT00656539
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 11, 2026, 2:54 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis

NCT01408082
View directory record Official record
Conditions
Blepharitis
Interventions
ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined), Azasite, Dexamethasone, Vehicle
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
45
States / cities
Chandler, Arizona • Phoenix, Arizona • Glendale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 11, 2026, 2:54 AM EDT
Completed Phase 2 Interventional

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period

NCT00892970
View directory record Official record
Conditions
Blepharitis
Interventions
Azithromycin ophthalmic solution, 1%, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
33
States / cities
Little Rock, Arkansas • Artesia, California • Azusa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 11, 2026, 2:54 AM EDT
Completed Phase 4 Interventional

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease

NCT01014078
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Azithromycin Ophthalmic Solution, 1%, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 11, 2026, 2:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

NCT00575367
View directory record Official record
Conditions
Bacterial Infections, Eye Infections
Interventions
AzaSite (azithromycin ophthalmic solution), Vigamox (moxifloxacin hydrochloride ophthalmic solution)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Sep 11, 2026, 2:54 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

NCT00629941
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Lewiston, Maine • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 11, 2026, 2:54 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis

NCT01560962
View directory record Official record
Conditions
Blepharitis
Interventions
povidone iodine, No Intervention, Azithromycin, tobramycin-dexmethasone, warm soaked eyelid wash
Drug · Other
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 11, 2026, 2:54 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis

NCT00629590
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Wantagh, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 11, 2026, 2:54 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis

NCT00629980
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
9
States / cities
Artesia, California • Mission Hills, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 11, 2026, 2:54 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)

NCT01220258
View directory record Official record
Conditions
Posterior Blepharoconjunctivitis
Interventions
Azithromycin ophthalmic solution, 1%
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 11, 2026, 2:54 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

NCT01797107
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Azasite
Drug
Lead sponsor
Philadelphia Eye Associates
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Sep 11, 2026, 2:54 AM EDT
Completed Phase 2 Interventional

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

NCT00894530
View directory record Official record
Conditions
Blepharitis
Interventions
Azithromycin ophthalmic solution, 1%, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
26
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Artesia, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Sep 11, 2026, 2:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery

NCT00575380
View directory record Official record
Conditions
Bacterial Infections, Eye Infections, Cataract Extraction
Interventions
AzaSite Eye Drops, Vigamox Eye Drops
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
21 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Mission Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Sep 11, 2026, 2:54 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)

NCT00105469
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
AzaSite, Tobramycin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Year and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
26
States / cities
Birmingham, Alabama • Littleton, Colorado • Atlantis, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 11, 2026, 2:54 AM EDT
Completed Phase 4 Interventional

A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)

NCT01105624
View directory record Official record
Conditions
Contact Lens Dry Eye
Interventions
azithromycin ophthalmic solution, 1%, Visine® for Contacts®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 11, 2026, 2:54 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

NCT01102244
View directory record Official record
Conditions
Blepharitis
Interventions
Tobradex ST, Azasite
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 11, 2026, 2:54 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)

NCT00105534
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
AzaSite, Vehicle
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Months and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
32
States / cities
Flagstaff, Arizona • Cudahy, California • Petaluma and Santa Rosa, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Sep 11, 2026, 2:54 AM EDT